肿瘤内高肿瘤芽在接受新辅助化疗的乳腺癌患者中的临床病理意义和预测价值。
Clinicopathological Significance and Predictive Value of High Intratumoral Tumor Budding in Patients With Breast Carcinoma Treated With Neoadjuvant Chemotherapy.
机构信息
Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
出版信息
Anticancer Res. 2023 May;43(5):2323-2332. doi: 10.21873/anticanres.16397.
BACKGROUND/AIM: The clinicopathological significance and predictive value of tumor budding (TB) in patients with breast carcinoma (BC) treated with neoadjuvant chemotherapy (NAC) have not been fully elucidated. This study aimed to evaluate the role of TB in predicting the response to NAC in patients with BC.
PATIENTS AND METHODS
We reviewed the pre-NAC biopsy slides obtained from 81 patients with BC and assessed the number of intratumoral TB. The association between TB and response to NAC and clinicopathological characteristics was evaluated.
RESULTS
High TB (≥10 per 20× objective field), which was associated with more frequent lymph node metastasis and lower pathological complete response (pCR) rate, was observed in 57 (70.2%) cases. Multivariate logistic regression analysis revealed that high TB independently predicted non-pCR.
CONCLUSION
High TB is associated with adverse features of BC. High TB on pre-NAC biopsy can be used as a predictive biomarker for non-pCR in NAC-treated patients with BC.
背景/目的：肿瘤芽（TB）在接受新辅助化疗（NAC）的乳腺癌（BC）患者中的临床病理意义和预测价值尚未完全阐明。本研究旨在评估 TB 在预测 BC 患者对 NAC 反应中的作用。
患者与方法
我们回顾了 81 例 BC 患者的新辅助化疗前活检切片，并评估了肿瘤内 TB 的数量。评估了 TB 与 NAC 反应和临床病理特征之间的关系。
结果
高 TB（≥20×物镜下 10 个）与更频繁的淋巴结转移和较低的病理完全缓解（pCR）率相关，在 57 例（70.2%）病例中观察到。多变量逻辑回归分析显示，高 TB 独立预测非 pCR。
结论
高 TB 与 BC 的不良特征相关。新辅助化疗前活检中的高 TB 可作为预测 BC 患者 NAC 治疗非 pCR 的生物标志物。
Zotero 插件